Royal Bank of Canada Raises Holdings in Invesco Pharmaceuticals ETF $PJP

Royal Bank of Canada grew its stake in shares of Invesco Pharmaceuticals ETF (NYSEARCA:PJP) by 479.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,377 shares of the company’s stock after acquiring an additional 51,619 shares during the quarter. Royal Bank of Canada’s holdings in Invesco Pharmaceuticals ETF were worth $6,472,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Quantinno Capital Management LP purchased a new stake in Invesco Pharmaceuticals ETF during the 1st quarter worth approximately $228,000. Cetera Investment Advisers lifted its stake in shares of Invesco Pharmaceuticals ETF by 250.7% during the first quarter. Cetera Investment Advisers now owns 20,462 shares of the company’s stock worth $2,123,000 after buying an additional 14,628 shares during the period. Simon Quick Advisors LLC acquired a new stake in shares of Invesco Pharmaceuticals ETF during the first quarter worth $384,000. Independent Financial Group LLC purchased a new stake in shares of Invesco Pharmaceuticals ETF during the first quarter valued at $330,000. Finally, IMC Chicago LLC acquired a new position in shares of Invesco Pharmaceuticals ETF in the 1st quarter valued at $318,000.

Invesco Pharmaceuticals ETF Price Performance

Shares of PJP stock opened at $124.74 on Wednesday. The business has a fifty day moving average of $117.82 and a 200 day moving average of $110.12. Invesco Pharmaceuticals ETF has a 1 year low of $86.81 and a 1 year high of $125.97. The firm has a market capitalization of $479.00 million, a price-to-earnings ratio of 15.59 and a beta of 0.45.

Invesco Pharmaceuticals ETF Company Profile

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. The Index consists of stocks of 30 United States pharmaceutical companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types.